CAR-T细胞疗法在多发性骨髓瘤中是否已到黄金时期?
该综述讨论CAR-T细胞在多发性骨髓瘤中的研究进展,BCMA是 promising 靶点,其他靶点包括CD19、CD38等。早期研究显示经重度预处理患者有 promising 缓解率但出现复发,细胞因子释放综合征和神经毒性多数为1-2级。复发可能由抗原逃逸和CAR-T细胞持久性有限介导,需更长期疗效和毒性数据。
要点
- BCMA是CAR-T治疗多发性骨髓瘤的 promising 靶点
- 早期研究显示重度预处理患者有 promising 缓解率但出现复发
- 细胞因子释放综合征和神经毒性多数为1-2级
核心结论
- CAR-T细胞在多发性骨髓瘤中显示 promising 活性,但复发、不良反应、成本和患者选择等挑战仍存,需更长期数据。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 早期临床研究显示经重度预处理患者有 promising 缓解率但出现复发。
- 细胞因子释放综合征和神经毒性在多数患者中观察到但多为1-2级。
- 复发可能由抗原逃逸和CAR-T细胞持久性有限介导。
关键数值与推荐
- 靶点包括BCMA、CD19、CD38、CD138、SLAMF7/CS1、轻链、GPRC5D和NKG2D。
- 靶向多抗原/表位或具有更高记忆表型T细胞比例的CAR-T构建体可能降低复发率。
- 同种异体CAR-T细胞提供「现货」选择正在开发中。
临床怎么用
- CAR-T细胞整合到骨髓瘤治疗需考虑疾病复发、不良反应、成本和确定合适患者人群。
局限性
- 需要更长期的疗效和毒性数据才能将CAR-T细胞用于多发性骨髓瘤的常规治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells have shown promising activity in hematological malignancies and are being studied for the treatment of multiple myeloma, as well. B-cell maturation antigen, which is widely and almost exclusively expressed on plasma cells and B cells, is a promising target. Other targets being evaluated include CD19, CD38, CD138, signaling lymphocyte activation molecule or CS1, light chain, GPRC5D, and NKG2D. Early clinical studies have shown promising response rates in heavily pretreated patients, but relapses have occurred. Cytokine release syndrome and neurotoxicity have been observed in the majority of patients but are mostly grades 1 and 2. Relapse may be mediated by antigen escape and the limited persistence of CAR T cells. CAR T-cell constructs that target multiple antigens/epitopes or constructs with longer persistence due to a higher proportion of memory phenotype T cells may decrease the rates of relapse. Allogeneic CAR T cells that offer "off-the-shelf" options are also being developed. The challenges in integrating CAR T cells in myeloma therapy include disease relapse, adverse effects, cost, and identifying the right patient population. Longer-term data on efficacy and toxicity are needed before CAR T cells are ready for prime time in myeloma.
引用
- Sidana S, Shah N. CAR T-cell therapy: is it prime time in myeloma? Blood Adv. 2019. PMID: 31714964. doi:10.1182/bloodadvances.2019000370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。